-
Bagnaia pips Marquez to French Grand Prix pole
-
Tchouameni can play Clasico despite Valverde clash: Real Madrid's Arbeloa
-
Conflict inflames tensions at Venice Biennale of Art
-
'No home left' for Gazans stranded in West Bank since Oct 7
-
Indonesia rescuers search for hikers killed in volcanic eruption
-
Magyar to become Hungary's 'regime change' PM
-
Wembanyama powers Spurs past T-Wolves as Knicks beat Sixers
-
Trapped seafarers traumatised by Gulf fighting: charities
-
European minnows bid to challenge social media giants
-
Red-hot Knicks open 3-0 playoff lead against Sixers
-
At 100th major, Aussie Scott sees best as yet to come
-
Scheffler and McIlroy fancied for PGA Championship title
-
Acting US attorney general pursues Trump grievances at Justice Dept
-
Spirit exit likely to lead to higher US airfares, experts say
-
World Cup to hold trio of star-studded opening ceremonies
-
Defending champ Jeeno grabs three-shot lead at windy Mizuho Americas Open
-
McIlroy says PGA should be open to returns from LIV Golf
-
Im leads Fleetwood by one at Quail Hollow
-
Peru presidential hopeful says electoral 'coup' underway
-
Mexico to cut school year short ahead of World Cup
-
Lens secure Champions League spot and send Nantes down
-
Dortmund down Frankfurt to push Riera close to the edge
-
Costa Rica's new leader vows 'firm land' against drug gangs
-
Messi says Argentina up against 'other favorites' in World Cup repeat bid
-
Global stocks diverge, oil rises as fresh US-Iran clashes hit peace hopes
-
Ailing Djokovic falls to early Italian Open exit ahead of Roland Garros
-
Costa Rica leader sworn in with tough-on-crime agenda
-
UK PM Starmer vows to fight on after local polls drubbing
-
Formula One engines to change again in 2027
-
Djokovic falls in Italian Open second round to qualifier Prizmic
-
NFL reaches seven-year deal with referees
-
Real Madrid fine Tchouameni and Valverde 500,000 euros over bust-up
-
Hantavirus scare revives Covid-era conspiracy theories
-
Report revives speculation China Eastern crash was deliberate
-
Allen ton powers Kolkata to fourth win in a row in IPL
-
Zarco dominates Le Mans qualifying as Marquez struggles
-
'Worst whistle' - Lakers coach blasts refs over LeBron treatment
-
French couple from virus-hit ship describe voyage as 'unlikely adventure'
-
Van der Breggen soars into women's Vuelta lead with stage six win
-
WHO says hantavirus risk low as countries prep repatriation flights
-
Stocks diverge, oil rises as fresh US-Iran clashes hit peace hopes
-
Zverev and Swiatek move into Italian Open third round
-
Celtic driven by fear of failure in Hearts chase, says O'Neill
-
Selling factories to Chinese partners: risky road for European carmakers
-
Rubio urges Europeans to share the Iran burden
-
France's Magnier sprints to victory in crash-hit Giro opener
-
Is there anybody out there? Pentagon releases secret UFO files
-
US job growth beats expectations but consumer confidence at all-time low
-
US fires on Iran tankers as talks hang in balance
-
German sports car maker Porsche to cut 500 jobs
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
M.Ouellet--BTB